FDA fails to approve cholesterol drug for kidney disease

WASHINGTON (Reuters) - U.S. health regulators amended the prescribing label for Merck & Co's cholesterol-lowering drug Vytorin to show it prevents heart problems in patients with chronic kidney disease, but stopped short of approving its use for that purpose. The decision means Merck cannot market Vytorin as a treatment for reducing the rate of heart problems in kidney patients, though it can ...

FDA label shows Merck cholesterol drug helps heart

WASHINGTON (Reuters) - U.S. health regulators amended the prescribing label for Merck & Co's cholesterol-lowering drug Vytorin to show it prevents heart problems in patients with chronic kidney disease, but stopped short of approving its use for that purpose. The decision means Merck cannot market Vytorin as a treatment for reducing the rate of heart problems in kidney patients, though it can ...

Research Indicates Popular Cholesterol Drug May Cause Diabetes

According to new research, the class of cholesterol-reducing medications known as statins may lead to a significantly elevated risk of type II diabetes in middle-aged and older women. However, experts say this doesn’t necessarily mean that people at risk of heart disease should stop taking them. Some medical experts say that instead of simply avoiding statins, people taking them should look for ...

Statins May Stave Off Liver Cancer in People With Hepatitis B

THURSDAY, Jan. 26 (HealthDay News) -- Popular cholesterol-lowering statins may also lower risk for liver cancer among people with hepatitis B, a new study shows. Hepatitis B, an inflammation of the liver due to the hepatitis B virus, is one of the main causes of liver cancer.

Statins may help beat breast cancer

Washington, Jan 20 (ANI): A new research has provided clues as to how cholesterol-reducing statins might help keep breast cancer at bay.